The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review

Nilforoushzadeh, Mohammad Ali; Heidari, Nazila; Heidari, Amirhossein; Ghane, Yekta; Lotfi, Zahra; Jaffary, Fariba; Najar Nobari, Minou; Najar Nobari, Niloufar

doi:10.1016/j.intimp.2024.111827

International Immunopharmacology

2024

DOI: 10.1016/j.intimp.2024.111827

|View full text |Cite

The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review

Mohammad Ali Nilforoushzadeh,

Nazila Heidari,

Amirhossein Heidari

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Systemic lupus erythematosus: pathogenesis and targeted therapy

Su,

Yu,

Lei

et al. 2024

Mol Biomed

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by dysregulated immune responses and autoantibody production, which affects multiple organs and varies in clinical presentation and disease severity. The development of SLE is intricate, encompassing dysregulation within the immune system, a collapse of immunological tolerance, genetic susceptibilities to the disease, and a variety of environmental factors that can act as triggers. This review provides a comprehensive discussion of the pathogenesis and treatment strategies of SLE and focuses on the progress and status of traditional and emerging treatment strategies for SLE. Traditional treatment strategies for SLE have mainly employed non-specific approaches, including cytotoxic and immunosuppressive drugs, antimalarials, glucocorticoids, and NSAIDs. These strategies are effective in mitigating the effects of the disease, but they are not a complete cure and are often accompanied by adverse reactions. Emerging targeted therapeutic drugs, on the other hand, aim to control and treat SLE by targeting B and T cells, inhibiting their activation and function, as well as the abnormal activation of the immune system. A deeper understanding of the pathogenesis of SLE and the exploration of new targeted treatment strategies are essential to advance the treatment of this complex autoimmune disease.

show abstract

Systemic lupus erythematosus: pathogenesis and targeted therapy

Su,

Yu,

Lei

et al. 2024

Mol Biomed

View full text Add to dashboard Cite

show abstract

The Immune Thrombocytopenia Treatment Landscape: A Focus on Patient Perspectives and Unmet Clinical Needs

Boreham

2024

EMJ Hematol

View full text Add to dashboard Cite

The limitations of currently available therapies for immune thrombocytopenia (ITP) mean that long-term responses are difficult to maintain, and patients face a substantial quality of life (QoL) burden imposed by both the disease and its treatment. During this Sanofi industry-supported symposium, leading experts in haematology discussed the significant unmet needs that exist in ITP, and highlighted the importance of new treatment approaches on the horizon with the potential to deliver improved clinical outcomes for patients. Waleed Ghanima, Consultant Hematologist at Østfold Hospital and Professor at the Institute of Clinical Medicine, University of Oslo, Norway, reviewed the key clinical considerations when choosing treatment for ITP and risk factors associated with established therapies. Cindy Neunert, Professor in the Department of Pediatrics and Section Head of Pediatric Hematology at Columbia University Irving Medical Center, Manhattan, New York, USA, explored patient preferences and goals of therapy in ITP, moving beyond platelet count to address important concerns such as fatigue and cognition. David J. Kuter, Chief of Hematology at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School, Boston, USA, highlighted the promise of emerging therapies on the horizon for ITP that address multiple mechanisms of disease pathology and may help to fill existing treatment gaps.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review

Cited by 2 publications

References 37 publications

Systemic lupus erythematosus: pathogenesis and targeted therapy

Systemic lupus erythematosus: pathogenesis and targeted therapy

The Immune Thrombocytopenia Treatment Landscape: A Focus on Patient Perspectives and Unmet Clinical Needs

Contact Info

Product

Resources

About